No black box warning on record for Pitavastatin

As of the latest FDA labeling reviewed, Pitavastatin (PITAVASTATIN CALCIUM) does not carry a black box warning. Standard warnings and precautions still apply — see the full Pitavastatin medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Myopathy and Rhabdomyolysis: Risk factors include age 65 or greater, renal impairment, uncontrolled hypothyroidism, concomitant use with certain other drugs, and higher doses of pitavastatin tablets. Discontinue pitavastatin tablets if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue pitavastatin tablets in patients experie

No black box warning on record for Pitavastatin

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Myopathy and Rhabdomyolysis: Risk factors include age 65 or greater, renal impairment, uncontrolled hypothyroidism, concomitant use with certain other drugs, and higher doses of pitavastatin tablets. Discontinue pitavastatin tablets if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue pitavastatin tablets in patients experie

Pitavastatin Black Box Warning

No black box warning on record for Pitavastatin

Other warnings & precautions

Pitavastatin Black Box Warning

No black box warning on record for Pitavastatin

Other warnings & precautions